Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company developing treatments for degenerative retinal diseases, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.
The event will take place in Miami, FL from March 10-12, 2025. The company's executive management team will host a fireside chat on Monday, March 10, 2025, at 3:00 pm ET.
Investors and interested parties can access the webcast through the 'Events' section on Belite Bio's investor relations website. The presentation recording will remain available for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BLTE gained 4.60%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Healthcare Conference being held on March 10-12, 2025, in Miami, FL. The Company will host a fireside chat on Monday, March 10, 2025, at 3:00 pm ET.
A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases that have significant unmet medical needs such as Stargardt disease type 1, or STGD1 and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, and is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at http://www.belitebio.com.
Media Relations Contact:
Jennifer Wu
ir@belitebio.com
Investor Relations Contact:
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) presenting at the Leerink Partners Conference 2025?
How can investors watch Belite Bio's (BLTE) Leerink Conference presentation?
How long will Belite Bio's (BLTE) Leerink Conference presentation be available for replay?
What is Belite Bio's (BLTE) main focus in drug development?
